Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2026-03-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
独立董事2025年度述职报告 （蔡文武）
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report of an independent director (蔡文武) for the year 2025 at 绿康生化股份有限公司. It includes information about attendance at board and shareholder meetings, committee participation, communication with auditors, and governance activities. The document is a narrative report on the director's duties and activities rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it a brief announcement or proxy solicitation. The content aligns with a management or board-related report focusing on governance and director duties. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters, but it is a substantive report, not a mere announcement, so it is not RPA or RNS.
2026-03-09 Chinese
关于修订《公司章程》及相关制度的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's Articles of Association and related internal rules. It details the reasons for the amendments, specific changes to the Articles, and the process for shareholder approval. There are no financial statements, audit opinions, or detailed financial data presented. The document is a formal disclosure of governance-related changes and procedural updates, not a full report or financial filing. It fits the category of Governance Information (CGR) as it pertains to company internal rules and governance practices.
2026-03-09 Chinese
关于公司2025年度拟不进行利润分配的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision not to distribute profits for the fiscal year 2025. It includes details about the audited net loss, cumulative undistributed profits, and compliance with stock exchange listing rules. The document references the board meeting resolution and the 2025 audit report but does not contain the full audit report or detailed financial statements itself. The length is short (1777 characters), and the content is primarily an announcement of a profit distribution decision rather than a full financial report. Therefore, it fits best as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2026-03-09 Chinese
非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a detailed summary table of non-operating fund occupation and other related party fund transactions for the year 2025, including balances, amounts, interest, and repayments. It is approved by the board and signed by the legal representative and accounting officers. The content is financial and operational data related to related party transactions, but it is not a full annual or interim report, nor an earnings release or audit report. It is a specific financial disclosure related to related party transactions, which typically falls under regulatory filings or disclosures. The document length is short (1696 characters), and it is a standalone summary table rather than a full report. There is no indication it is an announcement or presentation. Given the nature and format, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous financial disclosures that do not fit other specific categories.
2026-03-09 Chinese
独立董事2025年度述职报告 （狄旸，已离职）
Board/Management Information Classification · 95% confidence The document is an independent director's annual performance report for the year 2025, detailing the director's duties, attendance at board and committee meetings, communication with internal audit and accounting firms, and evaluation of company governance and compliance. It includes information on board nominations, remuneration, internal controls, and other governance matters. The document is a detailed report on the director's management and governance activities rather than a financial report or announcement. It fits the category of Board/Management Information (MANG) as it relates to board member duties and governance activities, including changes in board composition and management roles. The document length and content confirm it is a full report, not a brief announcement or certification.
2026-03-09 Chinese
独立董事2025年度述职报告 （方吉鑫）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Performance Report" for a specific individual, 方吉鑫, at 绿康生化股份有限公司. It details the director's attendance at board and shareholder meetings, communication with auditors, compliance with laws and regulations, and overall evaluation of their duties during the 2025 year. The content focuses on the director's role, responsibilities, and activities rather than financial results or company-wide management reports. It is a detailed report on board/management information specifically about an independent director's performance and duties. It is not an annual report, earnings release, or regulatory filing. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3342 characters, which is sufficient for a detailed report but not a full financial report. Confidence is high given the clear focus on director duties and board activities.
2026-03-09 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.